

LAVERDIA®-CA1 (verdinexor tablets)

Make it meaningful time.

For your next lymphoma patient, consider **Laverdia®-CA1** as a treatment option.

- Kills cancer cells at the nuclear core
- Twice weekly oral dose
- Affordable and convenient
- Not likely to cause P-glycoprotein-mediated multidrug resistance¹

Always wear chemotherapy resistant gloves when handling and administering the tablets to the dog and cleaning up its biological waste.



Important Safety Information

For use in dogs only. Laverdia®-CA1 (verdinexor tablets) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for **3 days** following treatment. Laverdia-CA1 can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling Laverdia-CA1 to avoid direct exposure to moistened, broken or crushed tablets or biological waste from the treated dog (feces, urine, saliva, or vomit). Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia-CA1 is a possible teratogen and can affect female and male fertility. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, lethargy, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia. Please see package insert or visit dechra-us.com for full prescribing information.

Reference

1. Mealey KL, Burke NS. Assessment of verdinexor as a canine P-glycoprotein substrate. J Vet Pharmacol Ther. 2023 Jul;46(4):264-267.

Dechra is a registered trademark of Dechra Pharmaceuticals Limited. Laverdia is a registered trademark of Dechra Limited. C240241

sound
byte


Dechra
Veterinary Products

LAVERDIA[®]-CA1 (verdinexor tablets)

Laverdia-CA1 is conditionally approved by the FDA. This means for this indication (i.e., the treatment of lymphoma), effectiveness has not been fully demonstrated; but the product has demonstrated a reasonable expectation that it is effective.



LAVERDIA-CA1 is a trademark of Dechra Limited. Dechra is a registered trademark of Dechra Pharmaceuticals PLC.

sound byte

CHECK-OFF &
ECHO NOTES

First, always ask if a Dechra representative has been in contact recently:

Doctor, what would you think about an oral treatment option for canine lymphoma?

Confirm and discuss the risks and benefits.

State the Issue

Ms. Smith, referring Charlie to an oncology specialist to treat his canine lymphoma the best option.

State the Solution

In an oncology referral is not a viable option, another option is Laverdia, a twice weekly at home oral pill that is approved to treat lymphoma in dogs like Charlie.

Make Your Recommendation

Ms. Smith, we have multiple options to help treat Charlie's lymphoma. If seeing an oncologist isn't something you are able to do, another option is Laverdia and can help slow the progression of the disease.